Cencora account plan
pharmaceutical distribution and services
At a glance
Cencora is a global pharmaceutical sourcing and distribution company with $321.3 billion of FY2025 revenue and more than 51,000 employees.
Cencora, formerly AmerisourceBergen and based in Conshohocken, PA, distributes brand-name, specialty and generic pharmaceuticals to hospitals, health systems, pharmacies, physician practices and veterinarians, and sells logistics, consulting and data services to drug manufacturers. It operates in over 50 countries, with about 9% of revenue from international operations. In FY2025 (year to September 30, 2025) revenue was $321.3 billion, operating income $2.63 billion and net income attributable to Cencora $1,554 million. It had more than 51,000 employees, about 41% in the U.S., and describes itself as ranked #10 on the Fortune 500.
Business units
U.S. Healthcare Solutions
$290,982 million FY2025 revenue, about 91% of group revenueDistributes the full drug range to hospitals, health systems, retail and mail-order pharmacies and physician practices, with specialty distribution and services for oncology and retina practices. It owns 85% of Retina Consultants of America (RCA) and, since February 2, 2026, OneOncology. Q3 FY2026 revenue was $74.9 billion (+4.9%), with operating income of $966.2 million (+15.9%).
International Healthcare Solutions
$30,366 million FY2025 revenue, about 9% of group revenueAlliance Healthcare (European pharmaceutical wholesale, including supply to Boots in the U.K. under an agreement to 2031), Innomar, World Courier specialty logistics and the strategic parts of PharmaLex. FY2025 operating income fell 9.1% to $648 million on declines in specialty logistics and consulting, but Q3 FY2026 operating income rose 20.8% to $165.9 million.
Other (businesses under strategic review)
Created from Q1 FY2026 for businesses whose strategic alternatives are being explored: MWI Animal Health, Profarma and the remaining PharmaLex businesses. U.S. Consulting Services was divested in April 2026 and MWI Animal Health is to merge with Covetrus. Q3 FY2026 revenue was $2.3 billion and operating income $108.7 million.
Strategic priorities
- Specialty pharmaceutical platform
- The CEO calls Cencora's "differentiated specialty pharmaceutical platform" its first growth priority, built on specialty distribution, the RCA and OneOncology management services organizations, World Courier and health-system services. MSO expansion is limited to tuck-ins in oncology and retina.
- Digital transformation of the supply chain
- Teams use AI to anticipate product needs in demand forecasting, and the company launched AI-supported customer support tools. U.S. distribution centers run on a single ERP system.
- Portfolio focus
- Non-core businesses are being divested: U.S. hub consulting sold in April 2026, MWI Animal Health to merge with Covetrus, and strategic alternatives explored for Profarma and parts of PharmaLex.
- Talent and leadership change
- Eva Boratto joined as EVP and CFO and Samantha Hammock as EVP and CHRO in 2026, replacing Jim Cleary and Silvana Battaglia.
- Long-term growth framework
- Management reaffirmed 7% to 10% organic operating income growth, another 3% to 4% from capital deployment and 10% to 14% EPS growth.
Latest results
In Q3 FY2026 (quarter to June 30, 2026) revenue was $84.8 billion, up 5.1%, and adjusted diluted EPS rose 12.0% to $4.48. Adjusted operating income grew 17.0% to $1.2 billion, and the adjusted gross margin rose 61 basis points to 4.16%, lifted by OneOncology. U.S. growth came from specialty sales and GLP-1s (+$2.3 billion), offset by manufacturer list price cuts, a $2.4 billion revenue headwind, the loss of an oncology customer and lower sales to the large mail order customer. Fiscal 2026 adjusted EPS guidance was raised to $17.75-$17.95, with revenue growth of 4% to 6% and adjusted free cash flow of about $3.0 billion.
Investments and deals
- OneOncology acquisition
- On February 2, 2026 Cencora acquired the majority of OneOncology it did not own, for total fair value consideration of $7,387.1 million, including $4,648.7 million in cash, financed with $3.0 billion of senior notes and $1.5 billion of term loans.
- Retina Consultants of America
- An 85% interest in RCA was acquired on January 2, 2025 for $4,042.0 million in cash; RCA contributed $2.1 billion of revenue in FY2025.
- Capital expenditure
- Capex was $668.0 million in FY2025 for distribution network expansion and technology, and about $900 million is expected in FY2026.
- Share repurchases and dividend
- $1 billion of shares were repurchased in Q3 FY2026, a new $2.0 billion programme was authorised in May 2026, and the quarterly dividend is $0.60 per share.
Challenges and risks
- Drug-pricing policy
- Risks include IRA negotiated prices, Executive Order 14297 on most-favored-nation pricing, the CMS bona fide service fee rule, 340B rebate models and WAC price reductions.
- Customer concentration
- The top 10 customers were about 66% of FY2025 revenue; Walgreens and Boots about 25% and Evernorth Health Services about 13%. WBA was acquired by Sycamore Partners on August 28, 2025, and the new owners may seek changes to the relationship.
- Biosimilar conversions and slower GLP-1 growth
- Faster brand-to-biosimilar conversions at the large mail order customer and slower GLP-1 growth led Cencora to cut FY2026 revenue growth guidance to 4% to 6% from 7% to 9%.
- Opioid liabilities
- The accrued opioid liability was $4.3 billion at September 30, 2025, payable over the next 13 years.
- Cybersecurity and regulation
- A fiscal 2024 cybersecurity event led to data exfiltration, and the Drug Supply Chain Security Act's traceability requirements "will continue to increase the cost of our operations".
What leadership says
“Our investments in specialty, digital transformation and talent are strengthening our ability to support our customers across the healthcare ecosystem while positioning Cencora for sustainable long-term growth.”
“We serve as the backbone of the pharmaceutical supply chain”
“we have to demonstrate our value all the time”
“Biosimilars are good. Biosimilars are good for patients.”
Where a supplier can help
- AI for supply chain and customer support
- Digital transformation is a named growth priority, with AI already used for demand forecasting and customer support; suppliers of forecasting, automation and support tooling fit it.
- Warehouse and distribution technology
- About $900 million of FY2026 capex goes to distribution network expansion and technology, alongside continued warehouse automation.
- Services for oncology and retina practices
- The MSO value plan moves from integrating OneOncology and RCA to shared capabilities such as clinical trials, then new analytics services, which creates needs for clinical-trial, practice-management and analytics vendors.
- Traceability, compliance and security
- Drug Supply Chain Security Act traceability costs and the cybersecurity risk after the fiscal 2024 data exfiltration point to compliance, track-and-trace and security offerings.
- Divestiture and integration support
- Portfolio focus (the MWI-Covetrus merger, the PharmaLex and Profarma reviews) and acquisition integration call for advisory, separation and integration services.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Cencora?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Cencora Annual Report on Form 10-K, fiscal year ended September 30, 2025
- Cencora (formerly AmerisourceBergen, Conshohocken, PA) is "one of the largest global pharmaceutical sourcing and distribution services companies", serving providers and pharmaceutical and biotech manufacturers in human and animal health; more than 51,000 employees at September 30, 2025, about 41% U.S.-based.
- FY2025 (year to September 30, 2025): revenue $321.3 billion (+9.3%), gross profit $11.5 billion (+15.8%), operating income $2.63 billion (+20.8%), net income attributable to Cencora $1,554 million, diluted EPS $7.96 vs $7.53.
- Two reportable segments: U.S. Healthcare Solutions (revenue $291.0 billion, +9.7%; operating income $3,575 million, +21.8%, margin 1.23%) and International Healthcare Solutions (revenue $30.4 billion, +6.1%; operating income $648 million, -9.1%); about 9% of revenue came from international operations.
- Growth driven by specialty sales to health systems and physician practices and GLP-1 products (+$7.7 billion, +26.9%); the January 2, 2025 acquisition of an 85% interest in Retina Consultants of America (RCA) for $4,042.0 million cash lifted U.S. gross margin to 2.72%.
- Strategy: "executional excellence" in core distribution plus higher-margin adjacencies for manufacturers and providers; from Q1 FY2026 a new structure moves MWI Animal Health, Profarma, U.S. Consulting Services and parts of PharmaLex into "Other", businesses for which strategic alternatives are being explored.
- Heavy concentration: top 10 customers about 66% of revenue; Walgreens and Boots about 25% (and 38% of receivables), Evernorth Health Services about 13%; Walgreens agreements run to 2029, Boots to 2031; WBA was acquired by Sycamore Partners on August 28, 2025.
- PharmaLex goodwill impairment of $723.9 million (after $418.0 million in FY2024); capex $668.0 million, expected about $900 million in FY2026; opioid accrued liability $4.3 billion payable over 13 years.
- Key risks: drug-pricing policy (IRA negotiated prices, Executive Order 14297 on most-favored-nation pricing, the CMS bona fide service fee rule, 340B rebate models), WAC price changes, customer loss, cybersecurity and opioid litigation.
- Cencora Quarterly Report on Form 10-Q, quarter ended June 30, 2026 (Q3 fiscal 2026)
- Q3 FY2026 (quarter to June 30, 2026): revenue $84.75 billion (+5.1%), gross profit $3.61 billion (+24.1%), operating income $1.12 billion (+29.1%), net income attributable to Cencora $763.5 million, diluted EPS $3.94 vs $3.52.
- Nine months: revenue $249.0 billion (+4.8%), operating income $3.02 billion (+15.8%), diluted EPS $15.21 vs $9.70, lifted by a $1.1 billion gain on remeasuring the previously held OneOncology stake.
- New structure: U.S. Healthcare Solutions (Q3 revenue $74.9 billion, +4.9%; operating income $966.2 million, +15.9%), International Healthcare Solutions ($7.7 billion, +5.9%; $165.9 million, +20.8%) and Other (MWI Animal Health, Profarma and the remaining PharmaLex businesses; $2.25 billion, +6.9%).
- OneOncology acquired February 2, 2026 for total fair value consideration of $7,387.1 million ($4,648.7 million cash); it raised U.S. gross margin to 3.17% (+63 basis points) in the quarter.
- U.S. growth came from specialty sales and GLP-1s (+$2.3 billion, +25.5%), offset by brand price declines, the loss of an oncology customer and lower sales to the large mail order customer.
- U.S. Consulting Services divested in April 2026 after a $249.5 million impairment; a $102.0 million opioid liability reduction followed the dismissal of opioid litigation.
- Total debt $11.7 billion at June 30, 2026 after $3.0 billion of senior notes and $1.5 billion of term loans in February 2026; $1.0 billion of buybacks in nine months; a new $2.0 billion repurchase programme (May 2026); capex expected at about $900 million for FY2026.
- Cencora reports fiscal 2026 third quarter results (press release)
- Q3 FY2026 revenue $84.8 billion (+5.1%); GAAP diluted EPS $3.94; adjusted diluted EPS $4.48 (+12.0% from $4.00).
- Adjusted operating income $1.2 billion (+17.0%), adjusted operating margin 1.46%; adjusted gross margin 4.16% (+61 basis points), lifted by OneOncology.
- FY2026 adjusted diluted EPS guidance raised to $17.75-$17.95 (from $17.70-$17.90); revenue growth 4% to 6%; adjusted operating income growth 13% to 14%; U.S. segment operating income growth 14.5% to 15.5%; adjusted free cash flow about $3.0 billion; capex about $900 million.
- $1 billion of shares repurchased in the quarter, the amount previously expected by the end of calendar 2026.
- Segments: U.S. Healthcare Solutions $74.9 billion revenue (+4.9%), operating income $966.2 million (+15.9%); International $7.7 billion (+5.9%), $165.9 million (+20.8%); Other $2.3 billion, $108.7 million (+24.8%).
- New executives: Eva Boratto (EVP and CFO) and Samantha Hammock (EVP and CHRO); quarterly dividend $0.60 per share.
- CEO Robert P. Mauch: results "reflect the power of our pharmaceutical-centric strategy", with investments "in specialty, digital transformation and talent".
- Cencora Q3 fiscal 2026 earnings call (transcript)
- CEO Bob Mauch frames three priorities: a "differentiated specialty pharmaceutical platform", digital transformation (AI for demand forecasting), and talent and culture; new CFO Eva Boratto's first call.
- Q3 FY2026: adjusted operating income +17%, adjusted EPS +12%, $1 billion of buybacks at an average $268 per share; FY2026 adjusted EPS guidance raised to $17.75-$17.95.
- U.S. revenue $74.9 billion (+5%); manufacturer list price cuts were a $2.4 billion revenue headwind; GLP-1 sales +$2.3 billion; core U.S. operating income grew double digits excluding OneOncology and the lost oncology customer, up from 7% the prior quarter.
- OneOncology and RCA performing ahead of expectations; MSO value plan in three phases (integration, shared capabilities such as clinical trials, then new services); MSO expansion limited to tuck-ins in oncology and retina.
- Biosimilars: "Biosimilars are good" for Cencora; Part B buy-and-bill is the larger profit opportunity, Part D mostly a revenue hit.
- Policy: confident physician reimbursement will not be hurt by ASP and GLOBE changes or the 2028 IRA Part B price negotiation; 340B changes still being assessed.
- FY2027 modeling: the MWI Animal Health merger with Covetrus would be a $150 million operating income headwind (about $0.35 of EPS) if it closed mid-year; EyeSouth retina carve-out timing unknown; full guidance in November.
- Cencora Q2 fiscal 2026 earnings call (transcript)
- Q2 FY2026: adjusted diluted EPS $4.75 (+7.5%); revenue $78.4 billion (+4%); operating income $1.3 billion (+6%); FY2026 adjusted EPS guidance raised to $17.65-$17.90, but revenue growth cut to 4% to 6% (from 7% to 9%).
- Revenue cut explained by faster brand-to-biosimilar conversions at the large mail order customer and slower GLP-1 growth; IRA-driven WAC reductions a $2 billion revenue headwind (3% of U.S. growth).
- Three priorities from CEO Bob Mauch: digital transformation of the supply chain "backbone" (AI-supported customer support tools), specialty across channels (MSOs, World Courier, health systems via Accelerate Pharmacy Solutions), and portfolio focus (MWI Animal Health to merge with Covetrus, U.S. hub consulting sold).
- U.S. core operating income growth about 7% excluding OneOncology and the lost oncology customer, despite a $10 million weather and $10 million COVID-19 vaccine headwind.
- Long-term guidance reaffirmed: 7% to 10% organic operating income growth, 3% to 4% from capital deployment, 10% to 14% EPS growth.
- Share repurchases resume: $1 billion by calendar year-end; $1.3 billion of term loans to be repaid in the fiscal year.
- Mauch on manufacturers: confident of keeping dollar profit despite price cuts; distribution services contribute "about $80 billion a year to the health care system".
- Last call of CFO Jim Cleary, who retires as CFO in June.
Questions about Cencora
What does Cencora do?
Cencora is a pharmaceutical sourcing and distribution company. It supplies drugs to hospitals, pharmacies, physician practices and veterinarians, and sells logistics, consulting and commercialization services to drug manufacturers, in the U.S. and over 50 countries.
What is Cencora's revenue?
Revenue was $321.3 billion in FY2025 (year to September 30, 2025), up 9.3%, with operating income of $2.63 billion. For FY2026 the company guides to 4% to 6% revenue growth.
How many employees does Cencora have?
Cencora had more than 51,000 employees at September 30, 2025, about 41% of them in the U.S.
What is Cencora's strategy?
Its three growth priorities are a specialty pharmaceutical platform (including the RCA and OneOncology practice networks), digital transformation of the supply chain, and talent, while divesting non-core businesses such as MWI Animal Health.
Who leads Cencora?
Robert P. Mauch has been President and CEO since October 2024. Eva Boratto is EVP and CFO.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)